Receptor for Advanced Glycation End Products

A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2.

Also Known As:

AGE Receptor; AGER Protein; Amphoterin Receptor; RAGE (Receptor for Advanced Glycation End Products); Receptor for Advanced Glycation End Products (RAGE); Receptor for Advanced Glycation Endproducts; Receptor, Amphoterin; Advanced Glycation End Product Receptor; Advanced Glycation End Product Receptors; Receptor For Advanced Glycation End Product; Receptor for Advanced Glycation Endproduct

Networked: 1836 relevant articles (31 outcomes, 170 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schmidt, Ann Marie: 95 articles (04/2022 - 05/2002)
2.	Yamamoto, Yasuhiko: 38 articles (05/2022 - 03/2003)
3.	Yamamoto, Hiroshi: 35 articles (10/2021 - 03/2003)
4.	Bierhaus, Angelika: 29 articles (01/2016 - 06/2004)
5.	Ramasamy, Ravichandran: 26 articles (04/2022 - 11/2003)
6.	Yamagishi, Sho-ichi: 22 articles (04/2015 - 02/2004)
7.	Nawroth, Peter P: 21 articles (01/2016 - 04/2003)
8.	Yan, Shi Fang: 19 articles (01/2018 - 05/2002)
9.	Sapin, Vincent: 17 articles (01/2022 - 03/2011)
10.	Oury, Tim D: 16 articles (01/2021 - 09/2003)

Related Diseases

1.	Inflammation (Inflammations) 10/01/2014 - "cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products." 01/01/2019 - "Recent studies suggest that the receptor for advanced glycation end products (RAGE) regulates endothelial permeability in inflammation. " 10/01/2023 - "The receptor for advanced glycation endproducts (RAGE) is an inflammatory receptor directly linking metabolic dysfunction with inflammation. " 09/04/2023 - "The receptor for advanced glycation end products (RAGE), which is widely expressed in the hippocampus, is a crucial factor in this inflammation and the associated cognitive deficits. " 05/09/2023 - "The receptor for advanced glycation end products (RAGE) is an important driver of chronic inflammation. "
2.	Insulin Resistance 01/01/2020 - "Recently, receptor for advanced glycation end products (RAGE) was found to be involved in the pathogenesis of insulin resistance (IR). " 01/01/2023 - "In addition, social isolation increased the expression of receptor for advanced glycation end-products (RAGE), consistent with impaired insulin sensitivity and weight gain linked to social isolation. " 11/08/2022 - "The receptor for advanced glycation end products (RAGE) plays an important role in obesity-associated insulin sensitivity. " 01/01/2016 - "Expression of the Receptor for Advanced Glycation End Products in Epicardial Fat: Link with Tissue Thickness and Local Insulin Resistance in Coronary Artery Disease." 05/01/2015 - "Soluble receptor for advanced glycation end products and insulin resistance during development of type 2 diabetes mellitus."
3.	Myocardial Ischemia (Ischemic Heart Diseases) 01/01/2022 - "Integrinβ3 mediates the protective effects of soluble receptor for advanced glycation end-products during myocardial ischemia/reperfusion through AKT/STAT3 signaling pathway." 01/01/2021 - "Protective Effects of the Soluble Receptor for Advanced Glycation End-Products on Pyroptosis during Myocardial Ischemia-Reperfusion." 05/02/2022 - "Soluble receptor for advanced glycation end-products (sRAGE) was reported to inhibit cardiac apoptosis through the mitochondrial pathway during myocardial ischemia/reperfusion (I/R) injury. " 01/01/2022 - "Soluble receptor for advanced glycation end-product (sRAGE) was reported to protect myocardial ischemia/reperfusion (I/R) injuries via directly interacting with cardiomyocytes besides competing with RAGE for AGEs. " 01/01/2020 - "Soluble receptor for advanced glycation end-products promotes angiogenesis through activation of STAT3 in myocardial ischemia/reperfusion injury."
4.	Type 2 Diabetes Mellitus (MODY) 04/01/2008 - "Receptor for advanced glycation end product polymorphisms and type 2 diabetes: the CODAM study." 08/28/2021 - "We did a systematic review and meta-analysis, aiming to examine the association of available polymorphisms in the receptor for advanced glycation end products (AGER) gene with the risk of type 2 diabetes. " 08/28/2021 - "Susceptibility of six polymorphisms in the receptor for advanced glycation end products to type 2 diabetes: a systematic review and meta-analysis." 12/08/2017 - "Genetic Variants of the Receptor for Advanced Glycation End-products in Susceptibility to Type 2 Diabetes Mellitus in Primary Hypertensive Patients." 10/01/2017 - "Genetic variants in the receptor for advanced glycation end products (RAGE) gene were associated with circulating soluble RAGE level but not with renal function among Asians with type 2 diabetes: a genome-wide association study."
5.	Diabetic Retinopathy (Retinopathy, Diabetic) 12/15/2019 - "Inhibition of receptor for advanced glycation end-products (RAGE) was effective in suppressing the development and progression of diabetic retinopathy." 01/01/2013 - "This study investigated the association between polymorphisms in the receptor for advanced glycation end products (RAGE) gene and the susceptibility to diabetic retinopathy (DR) in a Chinese population and identified a correlation between serum-soluble RAGE (sRAGE) levels and DR risk. " 02/01/2007 - "In the present study, the role of an AGE receptor, RAGE, was investigated in the development of diabetic retinopathy in vivo. " 05/01/2021 - "Association analysis of 374T/A (rs1800624) receptor for advanced glycation end-products (RAGE) gene polymorphism with diabetic retinopathy in Pakistani patients." 04/01/2021 - "The 429T/C receptor for advanced glycation end products gene polymorphism was found to be associated with severe non-proliferative diabetic retinopathy, and serum soluble receptor for advanced glycation end products levels had a positive correlation with severity of diabetic retinopathy."

Related Drugs and Biologics

1.	Advanced Glycation End Products
2.	Streptozocin (Streptozotocin)
3.	Glucose (Dextrose)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Telmisartan (Micardis)
6.	Nateglinide (Starlix)
7.	HMGB1 Protein (HMG1)
8.	Ligands
9.	Cytokines
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Artificial Respiration (Mechanical Ventilation)
4.	Stents
5.	Hepatectomy